WuXi Biologics (Cayman) (HKG:2269) said it entered a collaboration with Earendil Labs to support the development and manufacturing of multiple bispecific and multispecific antibodies and antibody-drug conjugate candidates, according to a Thursday press release.

Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation, and GMP manufacturing.

The programs are part of Earendil Labs' pipeline targeting autoimmune diseases, cancer, and other conditions.

WuXi Biologics said the collaboration aims to accelerate development timelines, improve manufacturing execution, and support global clinical advancement of the candidates.

Earendil Labs is an artificial intelligence-driven biotech company focused on developing next-generation biologics for autoimmune diseases, cancer, and other conditions, the statement said.